Sirolimus, a macrocyclic lactone, inhibits mammalian target of rapamycin (mTOR) thereby blocking cell division by interfering at the transition from G1 to S phase.28 People with diabetes show a breakdown in the phosphatidylinositol 3 kinase insulin signal transduction pathway, where mTOR has an important role,29 and this has been thought to limit the effectiveness of sirolimus in people with diabetes mellitus. Here, INS is linked to diabetes mellitus.